Immuron Limited - American Depositary Shares (IMRN)
2.1500
+0.0900 (4.37%)
NASDAQ · Last Trade: Oct 3rd, 7:24 PM EDT
Detailed Quote
Previous Close
2.060
Open
2.160
Bid
2.110
Ask
2.140
Day's Range
2.050 - 2.167
52 Week Range
1.500 - 2.738
Volume
135,300
Market Cap
383.30M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
49,880
Chart
About Immuron Limited - American Depositary Shares (IMRN)
Immuron Ltd is a biotechnology company focused on developing and commercializing innovative immunotherapeutic products aimed at treating various diseases, primarily those associated with the immune system and gastrointestinal health. The company uses its proprietary technology to create therapeutic agents that target specific pathways related to immune response, with applications in conditions such as traveler's diarrhea, inflammatory bowel disease, and other inflammatory disorders. Immuron is dedicated to advancing its research and development efforts to improve patient outcomes through targeted therapies that leverage the body's immune mechanisms. Read More
CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.
MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing.
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time).
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time).
MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
